Navigation Links
FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia
Date:3/24/2009

Indication Offers New Option for Adult Patients Suffering From Community-Acquired Bacterial Pneumonia

COLLEGEVILLE, Pa., March 24 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug Administration (FDA) approved TYGACIL(R) (tigecycline), for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens. TYGACIL was first approved by the FDA in 2005 for the treatment of complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI) caused by susceptible strains of indicated pathogens in adults.

"The approval of this new indication is timely. Antibiotic resistance continues to grow and new antimicrobials are needed," says Joseph Camardo, M.D., Senior Vice President, Global Medical Affairs, Wyeth Pharmaceuticals. "The approval of TYGACIL for CABP is an important milestone in Wyeth's commitment to exploring new treatment options in the anti-infective therapeutic area."

Thomas File, M.D., Chief of Infectious Disease Services for Summa Health System in Akron, Ohio, says, "CABP is a serious and potentially fatal respiratory disease that affects millions of Americans each year. The approval of TYGACIL for CABP means that physicians will have an additional option available to treat patients suffering from the disease."

CABP accounts for an estimated 4.5 million visits to physician offices, emergency departments, and outpatient clinics each year.

About the CABP Clinical Trials

The approval was based on results of two randomized, double-blind, active-controlled, multinational studies (Studies 308 and 313) that evaluated TYGACIL for the treatment of CABP in adults. The two studies (N=85
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. U.S. FDA Approves New THERAKOS(TM) CELLEX(TM) Photopheresis System
2. FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
3. FDA Approves Two Hologic HPV Tests
4. U.S. Food and Drug Administration Approves New Female Condom
5. Congress Approves FY2009 Omnibus Appropriations Bill with $900 Million for The Global Fund
6. FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout
7. State Health Department Approves Closure Plan for Brownsville Tri-County Hospital
8. NUCRYST Approves $0.80 Per Share Cash Distribution to Shareholders
9. Two Years after FDA Approves Silicone Breast Implants, Atlanta-area Cosmetic Plastic Surgeon Dr. Tom Lintner Discusses Their Safety
10. FDA Approves Camelina for Broiler Chickens
11. Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... The click strand woven bamboo flooring ... the business announces a click strand woven bamboo ... 2015. , Click strand woven bamboo flooring replicates ... well-known brand in the bamboo industry. It promises ... bamboo flooring supplier. , “We are happy to ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. TS-1 is an anti-cancer drug which is typically ... and is also used for treating gastric cancer and ... otastat potassium. The drug was first approved in 1999 ...
(Date:12/25/2014)... three months the trends for evening dresses shift ... one of the hottest styles in the next few months.” ... releases 26 A-line sweetheart evening dresses, and announces the availability ... are trying our best to help a lady to show ... affordable prices, we provide discounted delivery costs to our customers ...
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... International Cancer Research team has come out with the startling ... development of tumors in mice. This discovery could be vital ... molecules work by blocking the hormones that are essential for ... they strangle the tumor by blocking blood and nutrient supply ...
... turning their backs on tanning amid growing concerns over skin ... survey shows that teenagers are resisting the urge to tan ... 5,073 Australian adults and 699 Australian teenagers aged 12 to ... that 68 % of those aged 12-17 said they had ...
... part of the school curriculum from Class IX in all ... the age of 25. The new curriculum would be made ... the Human Resource Department of Government of India and National ... ministry has also made it compulsory to train teachers on ...
... have reacted with skepticism to a British man's claims that he ... some relief. // , ,In what is assumed as a ... now available in India. , ,This medicine is provided in ... that it would help the infected people to lead a much ...
... are unconcerned with the effect of their habit on the ... the damage // that smoking caused to the tongue or ... strangely reluctant to change their habits. This is of particular ... a massive awareness campaign as a part of the Mouth ...
... a doctor's permission is good at any time of life, ... study. // ,Thomas Foster and other scientists from the McKnight ... of rats that had lived to old age. Some were ... , ,Scientists examined chemical compounds in 41 tissue samples ...
Cached Medicine News:Health News:Aussie teens applauded for declining sun tan 2Health News:Regular light exercise slows down aging of the brain 2
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... Pa. and STOCKHOLM , ... (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced ... (CHMP) of the European Medicines Agency (EMA) has adopted ... clostridium histolyticum) for the treatment of adult men with ... of at least 30 degrees at the start of ...
(Date:12/22/2014)... 22, 2014  Eiger BioPharmaceuticals Incorporated announced the ... lonafarnib in patients with chronic hepatitis delta virus ... National Institutes of Health (NIH) Clinical Center in ... randomized, placebo-controlled, dose ascending study evaluated two doses ... mg twice daily for 28 days.  "This proof-of-concept ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... (Pink Sheets: MDBX ) ( www.thedispensingsolution.com ), ... to MDBX.  The company previously announced that their name ... The company is a leader in the design, manufacture ... The free-standing unit features 60 or more slots that ...
... 2011 This year, the melanoma community saw the first ... This major step forward will give more than 400 party-goers ... Gala.  They will gather at the Trump National Golf Club ... these cutting-edge advances and raise money for future research through ...
Cached Medicine Technology:MedBox Announces Ticker Symbol Change 2Washington, D.C. Melanoma Patient Community Celebrates Treatment Advances 2Washington, D.C. Melanoma Patient Community Celebrates Treatment Advances 3
Cushing-Hopkins periosteal elevator, Gutsch handle, blade width 7/16" (11 mm), length 7 5/8" (194 mm)....
Barr periosteal elevators....
Seldin periosteal elevators....
Williger periosteal elevators....
Medicine Products: